Omentin: a biomarker of cardiovascular risk in individuals with axial spondyloarthritis

• Main Authors: Fernanda Genre, Javier Rueda-Gotor, Sara Remuzgo-Martínez, Verónica Pulito-Cueto, Alfonso Corrales, Verónica Mijares, Leticia Lera-Gómez, Virginia Portilla, Rosa Expósito, Cristina Mata, Ricardo Blanco, Javier Llorca, Vanesa Hernández-Hernández, Esther Vicente, Cristina Fernández-Carballido, María Paz Martínez-Vidal, David Castro-Corredor, Joaquín Anino-Fernández, Carlos Rodríguez-Lozano, Oreste Gualillo, Juan Carlos Quevedo-Abeledo, Santos Castañeda, Iván Ferraz-Amaro, Raquel López-Mejías, Miguel Á. González-Gay
• Format: Article
• Language: English
• Published: Nature Publishing Group 2020-06-01
• Series: Scientific Reports
• Online Access: https://doi.org/10.1038/s41598-020-66816-x

Abstract Cardiovascular (CV) disease is the main cause of mortality in axial spondyloarthritis (axSpA). CV risk is enhanced by dysregulation of adipokines. Low omentin levels were associated with metabolic dysfunction and CV disease in conditions different from axSpA. Accordingly, we evaluated the genetic and functional implication of omentin in CV risk and subclinical atherosclerosis in a cohort of 385 axSpA patients. Subclinical atherosclerosis was evaluated by carotid ultrasound. Omentin rs12409609, in linkage disequilibrium with a polymorphism associated with CV risk, was genotyped in 385 patients and 84 controls. Serum omentin levels were also determined. omentin mRNA expression was assessed in a subgroup of individuals. Serum and mRNA omentin levels were lower in axSpA compared to controls. Low serum omentin levels were related to male sex, obesity, inflammatory bowel disease (IBD) and high atherogenic index. rs12409609 minor allele was associated with low omentin mRNA expression in axSpA. No association was observed with subclinical atherosclerosis at the genetic or functional level. In conclusion, in our study low omentin serum levels were associated with CV risk factors in axSpA. Furthermore, rs12409609 minor allele may be downregulating the expression of omentin. These data support a role of omentin as a CV risk biomarker in axSpA.